| Autor: |
Batistatou A; Department of Pathology, University of Ioannina Medical School, University Campus, PO Box 1186, 451 10, Ioannina, Greece. abatista@cc.uoi.gr, Charalabopoulos AK, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K |
| Jazyk: |
angličtina |
| Zdroj: |
Virchows Archiv : an international journal of pathology [Virchows Arch] 2006 Jun; Vol. 448 (6), pp. 763-7. Date of Electronic Publication: 2006 Mar 29. |
| DOI: |
10.1007/s00428-006-0183-8 |
| Abstrakt: |
Reduction/loss of E-cadherin is associated with the development and progression of many epithelial tumors, while in a limited number of neoplasms, E-cadherin is re-expressed in metastases. Dysadherin, recently characterized by members of our research team, has an anti-cell-cell adhesion function and downregulates E-cadherin in a posttranscriptional manner. Colorectal cancer (CRC) is one of the most common tumors in the developed world, and lymph node metastases are harbingers of aggressive behavior. The aim of the present study was to examine the dysadherin and E-cadherin expression patterns in lymph node metastases vs primary CRC. Dysadherin and E-cadherin expression was examined immunohistochemically in 78 patients with CRC, Dukes' stage C in the primary tumor and in one lymph node metastasis. Dysadherin was expressed in 42% while E-cadherin immunoreactivity was reduced in 45% of primary tumors. In lymph nodes, 33 and 81% of metastatic tumors were positive for dysadherin and E-cadherin, respectively. Dysadherin expression was not correlated with E-cadherin expression in the primary tumor with a reverse correlation evident in the lymph node metastases. Our results suggest that different mechanisms govern E-cadherin expression in the primary tumor and the corresponding lymph node metastases. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink